# LYNX1

## Overview
LYNX1 is a gene that encodes the protein Ly6/neurotoxin 1, which is a member of the Ly6/uPAR superfamily. This protein is characterized by a three-fingered fold structure, similar to that of snake venom α-neurotoxins, and functions as a GPI-anchored protein at the cell membrane (Loughner2016Organization; Miwa2019Lynx). Ly6/neurotoxin 1 acts as a negative allosteric modulator of neuronal nicotinic acetylcholine receptors (nAChRs), influencing receptor desensitization and recovery, particularly in the α4β2 subtype (Miwa2021Lynx1). This modulation plays a significant role in cognitive processes such as memory and learning, as well as in the regulation of plasticity within the central nervous system (Miwa2019Lynx). The protein's interactions with nAChRs also suggest potential protective roles against neurodegenerative diseases like Alzheimer's, and it is implicated in conditions such as Fragile X Syndrome and nicotine addiction (Anderson2020Modulation; Talvio2022Reduced).

## Structure
The LYNX1 protein is part of the Ly6/uPAR superfamily and is characterized by a three-fingered fold structure, similar to snake venom α-neurotoxins. This structure is stabilized by disulfide bonds, with LYNX1 typically containing 10-12 cysteines that form these bonds (Loughner2016Organization; Miwa2019Lynx). The protein's secondary structure includes two antiparallel beta-sheets, with one consisting of two strands in loop I and four strands across loops I-III. The second part of loop III is relatively disordered (Miwa2021Lynx1).

LYNX1 is a GPI-anchored protein, which allows it to attach to the cell membrane, although it can also exist in a secreted form (Loughner2016Organization; Tsetlin2015Threefinger). The protein's structure includes a large and mostly disordered loop III, which is distinct from the more rigid structure of snake neurotoxins and may contribute to its modulatory role on nicotinic acetylcholine receptors (nAChRs) (Tsetlin2015Threefinger; Miwa2019Lynx). The LYNX1 protein is part of the Ly6/uPAR/toxin superfamily and interacts with the extracellular domain of nAChRs, potentially restricting the transition between functional states of the receptor (Miwa2021Lynx1).

## Function
LYNX1 encodes a protein that is part of the Ly6/uPAR/neurotoxin superfamily and functions as an accessory protein to neuronal nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels involved in the cholinergic system. LYNX1 modulates nAChR function by promoting receptor desensitization and slowing recovery from desensitization, particularly in the ɑ4b2 nAChR subtype. This modulation affects memory, learning, and plasticity, acting as a suppressor in these processes (Miwa2021Lynx1).

LYNX1 is expressed throughout the central nervous system, with higher levels in the hippocampus, cortex, and cerebellum. It influences receptor function by altering agonist affinity, desensitization, and recovery from desensitization, and affects receptor assembly by favoring certain stoichiometries over others (Miwa2019Lynx). In the visual cortex, LYNX1 expression increases at the end of the critical period, reducing ocular dominance plasticity (Miwa2019Lynx).

LYNX1 also plays a role in the aging brain, modulating cholinergic-dependent plasticity and learning mechanisms. In adult Lynx1-/- mice, visual cortex plasticity is similar to that of juveniles, indicating LYNX1's role in restricting cortical plasticity (Loughner2016Organization).

## Clinical Significance
Alterations in the expression or function of the LYNX1 gene have been implicated in several neurological conditions. In the context of Fragile X Syndrome (FXS), a neurodevelopmental disorder, reduced LYNX1 expression in neural progenitor cells derived from human induced pluripotent stem cells has been observed. This reduction may lead to abnormalities in neuronal differentiation and network formation, contributing to cortical hyperexcitability and epilepsy in FXS (Talvio2022Reduced). 

In Alzheimer's disease, LYNX1 interacts with β-amyloid (Aβ1-42) and nicotinic acetylcholine receptors (nAChRs), potentially exerting protective effects against disease progression. A reduction in LYNX1 expression is associated with Alzheimer's pathology, and its modulation may influence cognitive decline (Anderson2020Modulation).

LYNX1 also plays a role in nicotine addiction. Its interaction with nAChRs affects receptor function, potentially influencing nicotine intake and relapse. The D398N mutation in LYNX1 is associated with higher nicotine intake and relapse in humans, highlighting its clinical significance in addiction (Miwa2019Lynx).

Additionally, LYNX1 is involved in sensorimotor gating, with knockout mice showing deficits in prepulse inhibition, a measure often disrupted in schizophrenia and other psychiatric disorders (Sherafat2021Differential).

## Interactions
LYNX1 is a protein that interacts with nicotinic acetylcholine receptors (nAChRs) as a negative allosteric modulator. It binds to various nAChR subunits, including α3-7, β2, and β4, and modulates receptor subtypes such as α4β2 and α7. These interactions affect agonist affinity, desensitization kinetics, receptor number at the cell surface, and single-channel kinetics (Anderson2020Modulation; Miwa2019Lynx). LYNX1 preferentially binds to α:α over β:β interfaces, particularly at the α4:α4 interface, influencing the stoichiometry and functional properties of nAChRs (Dong2020Dynamics).

LYNX1 competes with the β-amyloid peptide Aβ1-42 for binding to nAChRs, particularly affecting the α3, α4, α5, and α7 subunits. This competition suggests a protective role against Alzheimer's Disease pathology by blocking the inhibitory effects of Aβ1-42 on long-term potentiation (Anderson2020Modulation; Miwa2019Lynx). The interactions of LYNX1 with nAChRs are thought to occur at the cell membrane, with a significant association with individual α subunits or non-pentameric receptors (Anderson2020Modulation). LYNX1's role in modulating nAChR function is crucial for processes like mood regulation, learning, and addiction (Dong2020Dynamics).


## References


[1. (Tsetlin2015Threefinger) Victor I. Tsetlin. Three-finger snake neurotoxins and ly6 proteins targeting nicotinic acetylcholine receptors: pharmacological tools and endogenous modulators. Trends in Pharmacological Sciences, 36(2):109–123, February 2015. URL: http://dx.doi.org/10.1016/j.tips.2014.11.003, doi:10.1016/j.tips.2014.11.003. This article has 90 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.tips.2014.11.003)

[2. (Anderson2020Modulation) Kristin R. Anderson, Katie M. Hoffman, and Julie M. Miwa. Modulation of cholinergic activity through lynx prototoxins: implications for cognition and anxiety regulation. Neuropharmacology, 174:108071, September 2020. URL: http://dx.doi.org/10.1016/j.neuropharm.2020.108071, doi:10.1016/j.neuropharm.2020.108071. This article has 13 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.neuropharm.2020.108071)

[3. (Loughner2016Organization) Chelsea L. Loughner, Elspeth A. Bruford, Monica S. McAndrews, Emili E. Delp, Sudha Swamynathan, and Shivalingappa K. Swamynathan. Organization, evolution and functions of the human and mouse ly6/upar family genes. Human Genomics, April 2016. URL: http://dx.doi.org/10.1186/s40246-016-0074-2, doi:10.1186/s40246-016-0074-2. This article has 158 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40246-016-0074-2)

[4. (Miwa2021Lynx1) Julie M Miwa. Lynx1 prototoxins: critical accessory proteins of neuronal nicotinic acetylcholine receptors. Current Opinion in Pharmacology, 56:46–51, February 2021. URL: http://dx.doi.org/10.1016/j.coph.2020.09.016, doi:10.1016/j.coph.2020.09.016. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.coph.2020.09.016)

[5. (Sherafat2021Differential) Yasmine Sherafat, Edison Chen, Valeria Lallai, Malia Bautista, James P. Fowler, Yen-Chu Chen, Julie Miwa, and Christie D. Fowler. Differential expression patterns of lynx proteins and involvement of lynx1 in prepulse inhibition. Frontiers in Behavioral Neuroscience, November 2021. URL: http://dx.doi.org/10.3389/fnbeh.2021.703748, doi:10.3389/fnbeh.2021.703748. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnbeh.2021.703748)

[6. (Talvio2022Reduced) Karo Talvio, Rimante Minkeviciene, Kayla G. Townsley, Venkat Swaroop Achuta, Laura M. Huckins, Padraic Corcoran, Kristen J. Brennand, and Maija L. Castrén. Reduced lynx1 expression in transcriptome of human ipsc-derived neural progenitors modeling fragile x syndrome. Frontiers in Cell and Developmental Biology, November 2022. URL: http://dx.doi.org/10.3389/fcell.2022.1034679, doi:10.3389/fcell.2022.1034679. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2022.1034679)

[7. (Miwa2019Lynx) Julie M. Miwa, Kristin R. Anderson, and Katie M. Hoffman. Lynx prototoxins: roles of endogenous mammalian neurotoxin-like proteins in modulating nicotinic acetylcholine receptor function to influence complex biological processes. Frontiers in Pharmacology, April 2019. URL: http://dx.doi.org/10.3389/fphar.2019.00343, doi:10.3389/fphar.2019.00343. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2019.00343)

[8. (Dong2020Dynamics) Chuqiao Dong, Nathan R. Kern, Kristin R. Anderson, X. Frank Zhang, Julie M. Miwa, and Wonpil Im. Dynamics and interactions of gpi-linked lynx1 protein with/without nicotinic acetylcholine receptor in membrane bilayers. The Journal of Physical Chemistry B, 124(20):4017–4025, March 2020. URL: http://dx.doi.org/10.1021/acs.jpcb.0c00159, doi:10.1021/acs.jpcb.0c00159. This article has 6 citations.](https://doi.org/10.1021/acs.jpcb.0c00159)